Morphimmune Appoints Dr. Clay Siegall Chief Executive Officer and President

SEATTLE, WA, (March 22, 2023) – Morphimmune, Inc., a preclinical biotechnology company focused on developing targeted oncology therapeutics, today announced the appointment of Clay Siegall, Ph.D. as its CEO and President.

“Clay is a highly passionate and effective leader with a demonstrated ability to build significant value for an emerging biotechnology company,” said Isaac Barchas, Morphimmune’s Founding Board Chairman, co-founder and CEO of Research Bridge Partners, which made seed capital and follow-on investments in the company in 2020. “His emphasis on scientific and clinical excellence will drive Morphimmune’s development of novel targeted therapeutics with the goal to deliver significant benefit to cancer patients.” 

“I am pleased to join Morphimmune as CEO,” said Dr. Siegall. “Morphimmune’s targeted effector platform has the potential to deliver the next generation of oncology therapeutics. I look forward to advancing the company’s pipeline into the clinic while expanding its technology suite.”

“Clay immediately understood the vision for Morphimmune and is the right leader to advance our goal of saving patient lives,” said Dr. Philip Low, Morphimmune co-founder. 

Dr. Siegall previously served as the CEO and President of Seagen, Inc., which he co-founded in July 1997. Under his nearly 25 years of leadership, Seagen became the world leader in ADC therapeutics, earned FDA approvals for four cancer therapies, and grew to over $2 billion in annual revenue. During his tenure, he raised well over $1 billion of financing for Seagen from public and private markets and oversaw the company’s acquisition of Cascadian Therapeutics. Earlier this month, Pfizer, Inc. agreed to purchase Seagen for $43 billion.

Prior to Seagen, Dr. Siegall worked in positions of increasing responsibilities at Bristol Myers Squibb and the National Cancer Institute. He earned a Ph.D. in Genetics at George Washington University and a B.S. in Zoology at the University of Maryland.

Morphimmune was founded on the research of the company’s scientific co-founder Dr. Low, the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low previously founded Endocyte, which Novartis acquired for $2.1 billion in 2018. He has published more than 500 articles and has over 700 patents/patents pending, in addition to being the founder of seven companies to commercialize these discoveries.

About Morphimmune, Inc.

Morphimmune is a preclinical biotechnology company focused on developing targeted oncology therapeutics. The company’s proprietary Targeted Effector platform selectively delivers payloads to diseased cells. The targeted approach reduces toxicity and increases efficacy of known effector molecules, ultimately improving outcomes for patients. For more information, visit

For media inquiries, please contact